Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TTRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTurn Therapeutics reports Q1 2026 financial results
Filed May 11, 2026 · Period ending May 11, 2026 · ~1 min read
Key Changes
-
medium
Turn Therapeutics issued a press release announcing financial and operating results for the quarter ended March 31, 2026. Specific financial metrics are contained in the attached press release.
Item 2.02 verify on EDGAR → -
low
The 8-K filing serves as the formal notification of the earnings announcement, with detailed results provided in the separate press release (Exhibit 99.1).
8-K: Exhibits verify on EDGAR →
Summary
Turn Therapeutics filed an 8-K to announce its first quarter 2026 financial and operating results for the period ending March 31, 2026. This is a routine quarterly earnings disclosure, with the company issuing a press release on May 11, 2026, to communicate performance metrics to investors.
The actual financial details—revenue, expenses, cash position, and operational updates—are contained in the attached press release rather than in the 8-K body itself. For retail investors, this represents a standard quarterly reporting event. The materiality depends entirely on the content of the press release, which would show whether the company met, exceeded, or missed expectations.
Investors should review the full press release for specific financial metrics, management commentary on the quarter, and any updated guidance for the remainder of 2026. Watch for the company's cash runway and progress on clinical programs, which are typically key metrics for biotech firms like Turn Therapeutics.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 11, 2026, Turn Therapeutics Inc. issued a press release (the “Press Release”) announcing its financial and operating results for the quarter ended March 31, 2026.
The company disclosed its financial and operating results for the first quarter of 2026 ending March 31. The actual results are contained in the press release attached as Exhibit 99.1, which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Turn Therapeutics filed an 8-K attaching a press release dated May 11, 2026, with no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
99.1
Press Release, dated May 11, 2026
The company attached a press release dated May 11, 2026 as Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature of the disclosure cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify